secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001104659-26-005810
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics appoints Kevin J. Tracey to board; bylaws amended to lower shareholder vote threshold
--------------------------------------------------------------------------------

- Kevin J. Tracey, M.D., appointed to board effective Jan 21, 2026; awarded 1,220 RSUs under director compensation plan.
- Bylaw amendments: create cure process for shareholder nomination deficiencies; lower shareholder vote to amend bylaws from 80% to majority.
- Tracey is President/CEO of Feinstein Institutes, co-founder of SetPoint Medical; brings expertise in inflammation and bioelectronic medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/0001104659-26-005810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/tm263500d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-005810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer